FDA Approves Expanded Indication for Hyqvia to Treat Pediatr

During the 12-month trial period, Hyqvia was shown to be efficacious treating the occurrence of acute serious bacterial infections in children aged 2 through 16 years with primary immunodeficiency.

Related Keywords

United States , , Drug Administration , Deficiency Foundation , Jorey Berry , Immune Deficiency Foundation , Brandon Monk ,